Deferoxamine

**Indication**
Other specified sickle cell disorders or other haemoglobinopathies

**INN**
Deferoxamine

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

**EML status history**
First added in 2011 (TRS 965)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Wikipedia**
Deferoxamine

**DrugBank**
Deferoxamine

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended that oral deferasirox be transferred to the core list of the EML and EMLc for use in the treatment of transfusional iron overload in patients with thalassaemia syndromes, sickle cell disease and other chronic anaemias, with a square box listing specifying oral deferiprone as a therapeutic alternative. The Committee also recommended that intravenous deferoxamine should remain listed on the complementary list of the EML and EMLc for these indications, and the square box associated with the current listing be removed. The Committee accepted that the comparative efficacy and safety of deferiprone, deferoxamine and deferasirox were generally similar, and that orally administered treatments may be preferred options. The Committee recognized the value in having multiple iron chelating agents included on the Model Lists to enable countries to make appropriate national selection decisions taking into consideration relevant contextual factors.